Promore – Reports and prospectus

Prospectus (Promore) December 21, 2023 PMD Device Solutions AB – Company description	Company Description December 2023 (pdf)
Interim Reports (Promore) November 28, 2023 Interim report, January-September 2023	Report (pdf)
Interim Reports (Promore) August 30, 2023 Interim report January – June 2023	Report (pdf)
Interim Reports (Promore) May 23, 2023 Interim report January – March 2023	Report (pdf)
Annual Reports (Promore) May 9, 2023 Annual Report 2022	Report (pdf)
Interim Reports (Promore) February 28, 2023 Year-end report, 2022	Report (pdf)
Interim Reports (Promore) November 29, 2022 Interim report January – September 2022	Report (pdf)
Interim Reports (Promore) August 30, 2022 Promore Pharma Interim report January – June 2022	Report (pdf)
Interim Reports (Promore) May 17, 2022 Promore Pharma — interim report January-March 2022	Report (pdf)
Annual Reports (Promore) April 26, 2022 Annual Report 2021	Report (pdf)
Interim Reports (Promore) February 16, 2022 Interim report January – December 2021	Report (pdf)
Interim Reports (Promore) November 23, 2021 Interim report January – September 2021	Report (pdf)
Interim Reports (Promore) August 24, 2021 Interim report January – June 2021	Report (pdf)
Interim Reports (Promore) May 27, 2021 Interim report January – March 2021	Report (pdf)
Annual Reports (Promore) May 6, 2021 Annual Report 2020	Report (pdf)
Interim Reports (Promore) February 23, 2021 Year-end report 2020	Report (pdf)
Interim Reports (Promore) November 24, 2020 Interim report January – September 2020	Report (pdf)
Interim Reports (Promore) August 25, 2020 Promore Pharma AB (publ) Interim report January – June 2020	Report (pdf)
Interim Reports (Promore) May 26, 2020 Promore Pharma AB (publ) Interim report January – March 2020	Report (pdf)
Annual Reports (Promore) May 5, 2020 Annual Report 2019	Report (pdf)
Interim Reports (Promore) February 18, 2020 Promore Pharma AB (publ) Year-end report 2019	Report (pdf)
Interim Reports (Promore) November 22, 2019 Promore Pharma AB (publ) Interim report January – September 2019	Report (pdf)
Interim Reports (Promore) August 28, 2019 Promore Pharma AB (publ) Interim report January – June 2019	Report (pdf)
Interim Reports (Promore) May 21, 2019 Promore Pharma AB (publ) Interim report January – March 2019	Report (pdf)
Annual Reports (Promore) April 30, 2019 Annual Report 2018	Report (pdf)
Interim Reports (Promore) February 26, 2019 Promore Pharma AB (publ) Year-end report 2018	Report (pdf)
Interim Reports (Promore) November 23, 2018 Promore Pharma AB (publ) Interim report January – September 2018	Report (pdf)
Interim Reports (Promore) August 20, 2018 Interim report January – June 2018	Report (pdf)
Interim Reports (Promore) May 16, 2018 Promore Pharma AB (publ) Interim report January – March 2018	Report (pdf)
Annual Reports (Promore) April 25, 2018 Annual Report 2017	Report (pdf)
Interim Reports (Promore) February 6, 2018 Year-end report 2017	Report (pdf)
Interim Reports (Promore) November 21, 2017 Interim report January – September 2017	Report (pdf)
Interim Reports (Promore) August 30, 2017 Interim report January – June 2017	Report (pdf)
Interim Reports (Promore) May 19, 2017 Interim report January – March 2017	Report (pdf)
Annual Reports (Promore) May 17, 2017 Annual Report July 2015 – December 2016	Report (pdf)
Annual Reports (Promore) April 25, 2017 Pergamum AB – Annual Report July 2015 – December 2016	Report (pdf)
Annual Reports (Promore) January 29, 2016 Pergamum AB – Annual Report 20140701 – 20150630	Report (pdf)
Annual Reports (Promore) December 17, 2015 Lipopeptide AB - Annual Report 20140701–20150630	Report (pdf)

MESSAGE FROM THE CEO

Read what our CEO has to say about our business.

Read the CEO message

BUSINESS MODEL

The RespiraSense™ business model consists of several components that together create a complete delivery that generates attractive gross margins and recurring revenues.

Learn more about the business model

VISION

To avoid preventable respiratory failure events by transforming the standard of care in patient monitoring.

MISSION

To become the de facto standard-of-care for monitoring respiratory compromised patients in Europe and the US.